Fragment-based development of HCV protease inhibitors for the treatment of hepatitis C

Current Computer-Aided Drug Design

Volumn 8, Issue 1, 2012, Pages 55-61

  Karelson, Mati ^a   Dobchev, Dimitar A ^a,b   Karelson, Gunnar ^a,b   Tamm, Tarmo ^a,c   Tämm, Kaido ^a,d   Nikonov, Andrei ^c   Mutso, Margit ^c   Merits, Andres ^c  

^a The MolCode   (Estonia)

^b TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^c UNIVERSITY OF TARTU   (Estonia)

^d UNIVERSITY OF TARTU   (Estonia)

Author keywords

Fragment QSAR; HCV protease inhibitors; Hepatitis C; Multilinear regression

Indexed keywords

COMPUTATIONAL CHEMISTRY;

COMPUTATIONAL TECHNOLOGY; EFFICIENT PREDICTIONS; FRAGMENT QSAR; HCV PROTEASE INHIBITOR; HEPATITIS C; HEPATITIS C VIRUS; MULTILINEAR REGRESSION; PROSPECTIVES; PROTEASE INHIBITOR; TECHNOLOGY-BASED;

VIRUSES;

NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR;

ARTICLE; BIOLOGY; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; FRAGMENTATION REACTION; HEPATITIS C; HEPATITIS C VIRUS; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84857771062     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340912799218516     Document Type: Article

References (48)

1. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science, 1989, 244, 359-362.
2. Kuo, G.; Choo, Q.L.; Alter, H.J.; Gitnick, G.L.; Redeker, A.G.; Purcell, R.H.; Miyamura, T.; Dienstag, J.L.; Alter, M.J.; Stevens, C.E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244, 362-364.
3. Takano, S.; Nakamura, K.; Kawai, S.; Yokosuka, O.; Satomura, Y.; Omata, M. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology, 1996, 23, 708-712.
4. Deuffic-Burban, S.; Poynard, T.; Sulkowski, M.S.; Wong, J.B. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J. Viral. Hepat., 2007, 14, 107-115.
5. Micallef, J.M.; Kaldor, J.M.; Dore, G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral. Hepat., 2006, 13, 34-41.
6. Lindenbach, B.D.; Rice, C.M. Unraveling hepatitis C virus replication from genome to function. Nature, 2005, 436, 933-938.
7. Kolykhalov, A.A.; Mihalik, K.; Feinstone, S.M.; Rice, C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' non-translated region are essential for virus replication in vivo. J. Virol., 2000, 74, 2046-2051.
8. Perni, R.B.; Almquist, S.J.; Byrn, R.A.; Chandorkar, G.; Chaturvedi, P.R.; Courtney, L.F.; Decker, C.J.; Dinehart, K.; Gates, C.A.; Harbeson, S.L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B.G.; Taylor, W.P.; Thomson, J.A.; Tung, R.D.; Wei, Y.; Kwong, A.D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3 - NS4A serine protease. Antimicrob. Agents Chemother., 2006, 50, 899-909.
9. Lamarre, D.; Anderson, P.C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D.R.; Cartier, M.; Cordingley, M.G.; Faucher, A.-M.; Goudreau, N.; Kawai, S.H.; Kukolj, G.; Lagacé, L.; LaPlante, S.R.; Narjes, H.; Poupart, M.-A; Rancourt, J.; Sentjens, R.E.; George, T.S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y.S.; Weldon, S.M.; Yong, C.-L.; Llinàs- Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, 2003, 426, 186-189.
10. Strader, D.B.; Wright, T.; Thomas, D.L.; Seeff, L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004, 39, 1147-1171.
11. Manns, M.P.; Foster, G.R.; Rockstroh, J.K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov., 2007, 6, 991-1000.
12. Seiwert, S.D.; Andrews, S.W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P.T.; Misialek, S.; Stevens, S.K.; Stoycheva, A.; Hong, J.; Lim, S.R.; Qin, X.; Rieger, R.; Condroski, K.R.; Zhang, H.; Do, M.G.; Lemieux, C.; Hingorani, G.P.; Hartley, D.P.; Josey, J.A.; Pan, L.; Beigelman, L.; Blatt, L.M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother., 2008, 4432-4441.
13. Reiser, M.; Hinrichsen, H.; Benhamou, Y.; Reesink, H.W.; Wedemeyer, H.; Avendano, C.; Riba, N.; Yong, C.L.; Nehmiz, G.; Steinmann G.G. Antiviral efficacy of NS3- serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. J. Hepatology, 2005, 41, 832-835.
14. Klooster, G.A.E.; Vanwelkenhuysen, I.; Hooijmaijers, R.; Bol, K.; Voets, M.; Van Houdt, J.; Verloes, R.A.L.; Aharchi, F.; Marien, K.; Van Remoortere, P.; Broeckaert, F.; de Kock, H.; Simmen, K.A. Once daily regimens of the HCV NS3/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver. J. Hepatol., 2008, 48, S321.
15. Verloes, R.; Farha, K.A.; van Vliet, A.; Klooster, G.; Aharchi, F.; Marien, K.; de Kock, H.; Simmen, K. Results of a phase 1 placebocontrolled trial in healthy volunteers to examine the safety, tolerabilityand pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology, 2007, 46, 823A.
16. Lin, C.; Lin, K.; Luong, Y.-P.; Rao, B.G.; Wei, Y.-Y.; Brennan, D.L.; Fulghum, J.R.; Hsiao, H.-M.; Ma, S.; Maxwell, J.P.; Cottrell, K.M.; Perni, R.B.; Gates, C.A.; Kwong, A.D. In vitro resistance studies of hepatitis C virus serine protease inhibitors. J. Biol. Chem., 2004, 279, 17508-17514.
17. Lin, C.; Gates, C.A.; Rao, B.G.; Brennan, D.L.; Fulghum, J.R.; Luong, Y.-P.; Frantz, J.D.; Lin, K.; Ma, S.; Wei, Y.-Y.; Perni, R.B.; Kwong, A.D. In vitro studies of cross resistance mutations against two Hepatitis C virus serine protease inhibitors, VX-950 and BILN 206. J. Biol. Chem., 2005, 280, 36784-36791.
18. Tong, X.; Chase, R.; Skelton, A.; Chen, T.; Wright- Minogue, J.; Malcolm, B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res., 2006, 70, 28-38.
19. Reesink, H.W.; Zeuzem, S.; Weegink, C.J.; Forestier, N.; Van Vliet, A.; Van De Wetering De Rooij, J.; McNair, L.; Purdy, S.; Kauffman, R.; Alam, J.; Jansen, P.L.M. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 2006, 131, 997-1002.
20. Nurbo, J.; Peterson, S.D.; Dahl, G.; Danielson, U.H.; Karle, A.; Sandstrom, A.??- amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem., 2008, 16, 5590-5605.
21. Wei, H.; Lu, C.; Lin, T. Exploring the P2 and P3 ligand binding features for Hepatitis C virus NS3 protease using some 3D QSAR techniques. J. Mol. Graph. Model., 2008, 26, 1131-1144.
22. Venkatraman, S.; Njoroge, F. Macrocyclic inhibitors of HCV NS3-4A protease: design and structure activity relationship. Curr. Topics Med. Chem., 2007, 7, 1290-1301.
23. Chen, K.; Nair, L.; Vibulbhan, B.; Yang, W.; Arasappan, A.; Bogen, S.; Venkatraman, S.; Bennett, F.; Pan, W.; Blackman, M.L.; Padilla, A.; Prongay, A.; Cheng, K.; Tong, X.; Shih, N.; Njoroge, F. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J. Med. Chem., 2009, 52, 1370-1379.
24. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. Das, A.; Chakraborty, S.; Hong, S.; Tsay, S.; Hsu, M.; Ru Hwu, J. Nonnucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J. Med. Chem., 2009, 52, 1486-1490.
25. Raboisson, P.; de Kock, H.; Rosenquist, Å.; Nilsson, M.; Salvador- Oden, L.; Lin, T.; Roue, N.; Ivanov, V.; Wähling, H.; Wickström, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett., 2008, 18, 4853-4858.
26. Bogen, S.; Arasappan, A.; Pan, W.; Ruan, S.; Padilla, A.; Saksena, A.; Girijavallabhan, V.; Njoroge, F. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bioorg. Med. Chem. Lett., 2008, 18, 4219-4223.
27. Melagraki, G.; Afantitis, A.; Sarimveis, H.; Koutentis, P.; Markopoulos, J.; Igglessi-Markopoulou, O. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand - based virtual screening optimized procedure. Bioorg. Med. Chem., 2007, 15, 7237-7247.
28. Lara, J.; Wohlhueter R.; Dimitrova Z.; Khudyakov, Y. Artificial neural network for prediction of antigenic activity for a major conformational epitope in the hepatitis C virus NS3 protein. Bioinformatics, 2008, 24, 1858-1864.
29. Lowis, D. HQSAR: A New, Highly Predictive QSAR Technique, Tripos Technique Notes; Tripos:St. Louis, MO, USA, 1997.
30. Viswanadhan, V.; Mueller, G.; Basak, S.; Weinstein, J. Comparison of a neural net-based qsar algorithm (PCANN) with hologram and multiple linear regression-based QSAR approaches: application to 1,4-dihydropyridine-based calcium channel antagonists. J. Chem. Inf. Comput. Sci., 2001, 41, 505-511.
31. Du, Q.-S.; Huang, R.-B.; Wei, Y.T.; Pang, Z.-W.; Du, L.-Q.; Chou, K.-C. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J. Comput. Chem., 2009, 30, 295-304.
32. Casalegno M.; Sello G. Benfenati E: Top-priority fragment QSAR approach in predicting pesticide aquatic toxicity. Chem. Res. Toxicol., 2006, 19, 1533-1539.
33. Kuhne, R.; Ebert, R.-U.; Schuurmann, G. Chemical domain of QSAR models from atom-centered fragments, J. Chem. Inf. Model., 2009, 49, 2660-2669.
34. Ajmani, S.; Jadhav, K.; Kulkarni, S. Group-based QSAR (GQSAR): mitigating interpretation challenges in QSAR. QSAR Comb. Sci., 2009, 28, 36-51.
35. http://www.molcode.com/software, last accessed 04. May. 2011.
36. Karelson, M. Molecular Descriptors in QSAR/QSPR. Wiley & Sons: New York, 2000.
37. http://www.hyper.com/, last accessed 04. May. 2011.
38. Stewart, J. J. P. MOPAC Program Package 6.0. QCPE No. 455, 1990.
39. Dewar, M.J.S.; Zoebisch, E.G.; Healy, E.F.; Stewart, J.J.P. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 1985, 107, 3902-3909.
40. Katritzky, A.; Dobchev, D.; Slavov, S.; Karelson, K. Legitimate utilization of large descriptor pools for QSPR/QSAR models. J. Chem. Inf. Model., 2008, 48, 2207-2213.
41. Karelson, M.; Karelson, G.; Tamm, T.; Tulp, I.; Jänes, J.; Tämm, K.; Lomaka, A.; Savchenko, D.; Dobchev, D. QSAR study of pharmacological permeabilities. Arkivoc, 2009, ii, 218-238.
42. Bogen, S.; Arasappan, A.; Pan, W.; Ruan, S.; Padilla, A.; Saksena, A.K.; Girijavallabhan, V.; Njoroge, F.G. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bioorg. Med. Chem. Lett., 2008, 18, 4219-4223.
43. Nurbo, J.; Peterson, S.; Dahl, G.; Danielson, U.; Karle, A.; Sandstrom, A. beta-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem., 2008, 6, 5590-5605.
44. Ronn, R.; Lampa, A.; Peterson, S.; Gossas, T.; Akerblom, E.; Danielson, U.; Karlen, A.; Sandstrom, A. Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P 1 moiety. Bioorg. Med. Chem., 2008, 16, 2955-2967.
45. Liverton, N.; Holloway, M.; McCauley, J.; Rudd, M.; Butcher, J.; Carroll, S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K.; Mao, S.; McIntyre, C.; Nguyen, K.; Romano, J.; Stahlhut, M.; Wan, B.; Olsen, D.; Vacca, J. Molecular modeling based approach to potent P2 - P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc., 2008, 130, 4607-4609.
46. Chen, K.; Vibulbhan, B.; Yang, W.; Cheng, K.; Liu, R.; Zichardo, J.; Butkiewicz, N.; Njoroge, F. Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue. Bioorg. Med. Chem., 2008, 16, 1874-1883.
47. Li, C.; Nair, L.; Liu, T.; Li, F.; Pichardo, J.; Agrawal, S.; Chase, R.; Tong, X.; Uss, A.; Bogen, S.; Njoroge, F.; Morrison, R.; Cheng, K. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem. Pharmacol., 2008, 75, 1186-1197.
48. Arkive Database, supported by Arkivoc, http://www.arkat-usa.org/, last accessed 10 Oct. 2011.